Our subsequent randomized controlled trial (NCT05638594) is being conducted to validate the efficacy and safety of trastuzumab and pyrotinib plus dalpiciclib and letrozole as neoadjuvant therapy in patients with HR‐positive, HER2‐positive breast cancer, with the head‐to‐head comparator of trastuzumab and pertuzumab plus docetaxel and carboplatin. Here, ERBB2 is linked to breast cancer.